Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept trial of UCB5857 in primary Sjogren's syndrome
2014-004523-51Phase 2Terminated
- Sponsor
- UCB Celltech
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Sjögren's syndrome (SS) comparing UCB5857 with Placebo (2 arms). Primary endpoint: Change from baseline in ESSDAI. Started Apr 2015; status: terminated.
02
Drugs
seletalisib
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on 2014-004523-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004523-51.